Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective
Biomolecules · 11.07.2025 · 15 (7) · 990
DOI: 10.3390/biom15070990 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 11.07.2025. Verfasst von Yan Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Na…. Hauptthemen laut MEDLINE: Lipoproteins, VLDL, Fatty Liver. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: he Science and Technology Program of Guangzhou, China, the Guangdong Demonstration Base for Joint Cultivation of Postgraduates, Science and Technology Program of Guangzhou, China.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive accumulation of triglycerides and other lipids within liver cells and is closely associated with cardiovascular disease and metabolic syndrome. Very low-density lipoprotein (VLDL) is a lipoprotein synthesized and secreted by the liver and is primarily responsible for transporting triglycerides from the liver to peripheral tissues. Therefore, there is a strong association between MASLD and VLDL. Studies have found that excess production and abnormal metabolism of VLDL can lead to elevated blood triglyceride levels, which in turn promote fat deposition in the liver, leading to MASLD. During the pathophysiological process of MASLD, adipokines and inflammatory mediators secreted by adipose tissue can affect the metabolic network of the liver, further aggravating VLDL metabolic disorders. This paper reviews the effects of VLDL synthesis and metabolism on the development of MASLD, including the changes in VLDL structure and composition, the biosynthesis of VLDL, and the mechanism of underlying VLDL-associated damage, in an attempt to elucidate the intricate crosstalk between MASLD and VLDL, in order to provide new perspectives and methods for the prevention and treatment of related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Natural Products and Drugs, Guangdong Pharmaceutical University, Guangzh…
- Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong TCM Key Laboratory for Metabolic Disease…
- Key Laboratory of State Administration of Traditional Chinese Medicine for Production & Development of Cantonese Medicinal Materials, Guangzhou Comprehensive Experimental Station of National Industrial Technology System…
ORCID-Profile: Zhengquan Su
Förderung
- he Science and Technology Program of Guangzhou, China
- the Guangdong Demonstration Base for Joint Cultivation of Postgraduates
- Science and Technology Program of Guangzhou, China
- Guangdong Demonstration Base for Joint Cultivation of Postgraduates
Zitieren
APA
Chen, Y., Lei, K., Liu, Y., Liu, J., Wei, K., Guo, J., & Su, Z. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective. Biomolecules, 15(7), 990. https://doi.org/10.3390/biom15070990
Vancouver
Chen Y, Lei K, Liu Y, Liu J, Wei K, Guo J, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective. Biomolecules. 2025;15(7):990. doi:10.3390/biom15070990
BibTeX
@article{Chen2025,
author = {Chen, Yan and Lei, Kaiwen and Liu, Yanglong and Liu, Jianshen and Wei, Kunhua and Guo, Jiao and Su, Zhengquan},
title = {Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {7},
pages = {990},
doi = {10.3390/biom15070990}
}
EUVIMED